Association Between Major Bleeding and In-Hospital Major Adverse Cardiovascular Events After Percutaneous Coronary Intervention in Acute Coronary Syndromes

Abstract

Background

Major bleeding (MB) is a serious complication in patients with acute coronary syndromes (ACS) undergoing percutaneous coronary intervention (PCI). Although its association with long-term adverse outcomes is well documented, the impact of in-hospital MB on early cardiovascular prognosis remains incompletely characterized.

Objective

To investigate the association between in-hospital MB and major adverse cardiovascular events (MACE) in patients with ACS treated with PCI.

Methods

We conducted a retrospective cohort study on 829 consecutive ACS patients who underwent successful PCI between January 2021 and December 2023. MB was defined as Bleeding Academic Research Consortium (BARC) type 3 or 5 bleeding events. MACE was defined as a composite of all-cause mortality, recurrent myocardial infarction, ischemic stroke, urgent target vessel revascularization, or new-onset/decompensated heart failure with left ventricular ejection fraction (LVEF) <30%. Clinical data and outcomes were extracted from hospital records and independently adjudicated.

Results

MB occurred in 4.5% of patients (n = 37). The incidence of in-hospital MACE was significantly higher among patients with MB compared to those without (40.5% vs. 8.1%, p < 0.001). In multivariate logistic regression, MB was the strongest independent predictor of in-hospital MACE (OR: 12.43, 95% CI: 3.43–44.98, p < 0.001), followed by reduced LVEF (OR per % increase: 0.794, 95% CI: 0.747–0.843, p < 0.001), age, and white blood cell count.

Conclusions

In-hospital MB is a potent and independent predictor of early MACE in patients with ACS undergoing PCI. These findings emphasize the need for careful risk stratification, bleeding prevention strategies, and individualized antithrombotic management in this high-risk population.

Keywords

acute coronary syndrome - percutaneous coronary ıntervention - major bleeding - major adverse cardiovascular events - dual antiplatelet therapy - BARC bleeding criteria - in-hospital outcomes

Publication History

Received: 01 June 2025

Accepted: 22 July 2025

Article published online:
14 August 2025

• References

• 1 O'Gara PT, Kushner FG, Ascheim DD. et al. 2013 ACCF/AHA guideline for the management of ST-elevation myocardial infarction. J Am Coll Cardiol 2013; 61 (04) e78-e140
• 2 Mehran R, Rao SV, Bhatt DL. et al. Standardized bleeding definitions for cardiovascular clinical trials: a consensus report from the Bleeding Academic Research Consortium. Circulation 2011; 123 (23) 2736-2747
• 3 Vavalle JP, Rao SV. Impact of bleeding complications on outcomes after PCI. Am J Cardiol 2009; 103 (09) 1204-1209
• 4 Kwok CS, Sirker A, Rawat S. et al. Major bleeding after PCI and mortality. Int J Cardiol 2015; 201: 77-84
• 5 Sun Y, Zhang H, Liu L. et al. In-hospital major bleeding and cardiovascular events in Chinese ACS patients. Thromb Res 2022; 214: 37-43
• 6 Campbell PG, Simon DI. Bleeding events and inflammatory markers. Am J Cardiol 2011; 108 (08) 1105-1111
• 7 Yeh RW, Sidney S, Chandra M, Sorel M, Selby JV, Go AS. Complications and mortality following PCI. Circulation 2012; 125 (09) 1234-1241
• 8 Généreux P, Giustino G, Witzenbichler B. et al. Relation between coronary calcium and bleeding after PCI. JACC Cardiovasc Interv 2014; 7 (11) 1400-1409
• 9 Choi SS, Sergie Z, Mehran R. Impact of in-hospital major bleeding on outcomes in acute coronary syndromes. Curr Opin Cardiol 2012; 27 (06) 669-674
• 10 Mehran R, Pocock S, Nikolsky E. et al. Impact of bleeding on mortality after PCI. Lancet 2012; 379 (9829): 1703-1711
• 11 Byrne RA, Rossello X, Coughlan JJ. et al; ESC Scientific Document Group. 2023 ESC Guidelines for the management of acute coronary syndromes. Eur Heart J 2023; 44 (38) 3720-3826
• 12 Matsuoka Y, Sotomi Y, Hikoso S. et al. The prognostic impact of in-hospital major bleeding and recurrence of myocardial infarction during acute phase after percutaneous coronary intervention for acute myocardial infarction. J Atheroscler Thromb 2024; 31 (02) 158-170
• 13 Mehran R, Baber U, Steg PG. et al. Cessation of dual antiplatelet treatment and cardiac events after PCI. N Engl J Med 2013; 368 (22) 2086-2097
• 14 Iyer M, Shah R, Zheng W. et al. Aetiology and predictors of major bleeding events in patients with heart failure with reduced ejection fraction undergoing percutaneous coronary intervention. Open Heart 2024; 11 (01) e002572
• 15 Sorrentino S, Giustino G, Baber U. et al. Dual antiplatelet therapy cessation and adverse events after drug-eluting stent implantation in patients at high risk for atherothrombosis (from the PARIS registry). Am J Cardiol 2018; 122 (10) 1638-1646
• 16 Valgimigli M, Costa F, Lokhnygina Y. et al. Trade-off of myocardial infarction vs. bleeding types on mortality after acute coronary syndrome: lessons from the Thrombin Receptor Antagonist for Clinical Event Reduction in Acute Coronary Syndrome (TRACER) randomized trial. Eur Heart J 2017; 38 (11) 804-810
• 17 Chhatriwalla AK, Amin AP, Kennedy KF. et al; National Cardiovascular Data Registry. Association between bleeding events and in-hospital mortality after percutaneous coronary intervention. JAMA 2013; 309 (10) 1022-1029 [published correction appears in JAMA. 2013 Aug 14;310(6):647]
• 18 Fu A, Barry Q, Boudreau R. et al. Outcomes of patients with high bleeding risks characteristics presenting with acute coronary syndrome undergoing percutaneous coronary intervention. Eur Heart J 2021; 42 (Suppl. 01) ehab724.1428
• 19 Freemantle N, Calvert M, Wood J, Eastaugh J, Griffin C. Composite outcomes in randomized trials: greater precision but with greater uncertainty?. JAMA 2003; 289 (19) 2554-2559
• 20 Armstrong PW, Westerhout CM, Van de Werf F. et al. Refining clinical trial composite outcomes: an application to the Assessment of the Safety and Efficacy of a New Thrombolytic-3 (ASSENT-3) trial. Am Heart J 2011; 161 (05) 848-854
• 21 Pocock SJ, Ariti CA, Collier TJ, Wang D. The win ratio: a new approach to the analysis of composite endpoints in clinical trials based on clinical priorities. Eur Heart J 2012; 33 (02) 176-182
• 22 Bakal JA, Roe MT, Ohman EM. et al. Applying novel methods to assess clinical outcomes: insights from the TRILOGY ACS trial. Eur Heart J 2015; 36 (06) 385-92a
• 23 Cenko E, Manfrini O, Bugiardini R. Net adverse clinical events with P2Y₁₂ inhibitor therapy in older patients after percutaneous coronary interventions. Atherosclerosis 2024; 390: 117434
• 24 Redfors B, Kirtane AJ, Liu M. et al. Dual antiplatelet therapy discontinuation, platelet reactivity, and adverse outcomes after successful percutaneous coronary intervention. JACC Cardiovasc Interv 2022; 15 (08) 797-806 [published correction appears in JACC Cardiovasc Interv. 2022 Oct 10;15(19):2001]
• 25 Baber U, Dangas G, Chandrasekhar J. et al. Ticagrelor with or without aspirin after PCI. N Engl J Med 2019; 381 (21) 2032-2042
• 26 Kwok CS, Sirker A, Rawat S. et al. Influence of major bleeding after percutaneous coronary intervention on mortality and cardiovascular outcomes. Int J Cardiol 2015; 201: 77-84
• 27 Vinayak M, Cao D, Tanner R. et al. Impact of bleeding risk and inflammation on cardiovascular outcomes after percutaneous coronary intervention. JACC Cardiovasc Interv 2024; 17 (03) 345-355
• 28 Tuomisto K, Jousilahti P, Sundvall J, Pajunen P, Salomaa V. C-reactive protein, interleukin-6 and tumor necrosis factor alpha as predictors of incident coronary and cardiovascular events and total mortality. A population-based, prospective study. Thromb Haemost 2006; 95 (03) 511-518
• 29 Kamphuisen PW, Rosendaal FR, Büller HR. Hemostatic abnormalities and arterial thrombosis. Semin Thromb Hemost 2009; 35 (05) 449-450
• 30 Brenner B, Lisman T. Hemostasis and thrombosis in extreme physiological and pathological conditions. Semin Thromb Hemost 2018; 44 (07) 615-616
• 31 Yoshii S, Nishikawa H, Watanabe K. et al. Endothelial dysfunction predicts bleeding and cardiovascular death in patients with acute coronary syndrome. J Cardiol 2023; 81 (02) 122-128
• 32 Campbell CL, Steinhubl SR, Hooper WC. et al. Bleeding events are associated with an increase in markers of inflammation in acute coronary syndromes: an ACUITY trial substudy. J Thromb Thrombolysis 2011; 31 (02) 139-145
• 33 Yeh RW, Sidney S, Chandra M. et al. Complications and mortality following percutaneous coronary intervention in contemporary practice: results from the NCDR. Circulation 2012; 125 (09) 1234-1241
• 34 Huang L, Zhao Y, Li J. et al. In-hospital major adverse cardiovascular events after primary PCI for STEMI: a real-world multicenter analysis. BMC Cardiovasc Disord 2023; 23: 235
• 35 Généreux P, Witzenbichler B, Weisz G. et al. Incidence, predictors, and impact of bleeding complications after PCI. JACC Cardiovasc Interv 2014; 7 (11) 1400-1409
• 36 Yamamoto K, Natsuaki M, Morimoto T. et al; CREDO-Kyoto PCI/CABG Registry Cohort-3 investigators. Ischemic and bleeding events after first major bleeding event in patients undergoing coronary stent implantation. Am J Cardiol 2022; 162: 13-23
• 37 Valgimigli M, Smits PC, Frigoli E. et al; MASTER DAPT Investigators. Duration of antiplatelet therapy after complex percutaneous coronary intervention in patients at high bleeding risk: a MASTER DAPT trial sub-analysis. Eur Heart J 2022; 43 (33) 3100-3114
• 38 Valgimigli M, Frigoli E, Heg D. et al; MASTER DAPT Investigators. Dual antiplatelet therapy after PCI in patients at high bleeding risk. N Engl J Med 2021; 385 (18) 1643-1655
• 39 Nissen PH, Pedersen OB. Unlocking the potential of microRNA expression: biomarkers for platelet reactivity and coronary artery disease. Semin Thromb Hemost 2025; . Epub ahead of print
• 40 Zhou M, Hou P, Liang Y. et al. Comparison of platelet function tests for long-term cardiovascular events after percutaneous coronary interventions. Semin Thromb Hemost 2025; . Epub ahead of print
• 41 Kang J, Rizas KD, Park KW. et al. Dual antiplatelet therapy de-escalation in acute coronary syndrome: an individual patient meta-analysis. Eur Heart J 2023; 44 (15) 1360-1370
• 42 Lattuca B, Silvain J, Yan Y. et al. Reasons for the failure of platelet function testing to adjust antiplatelet therapy: pharmacodynamic insights from the ARCTIC study. Circ Cardiovasc Interv 2019; 12 (11) e007749
• 43 Capranzano P, Angiolillo DJ. De-escalation of oral P2Y₁₂ inhibitors guided by platelet function testing in ACS patients undergoing PCI: impact of diabetes mellitus. EuroIntervention 2019; 15 (06) e486-e489